{"claims": [{"text": "all C-3 aryl compounds showed modest α5 advantage irrespective of the specific aryl group", "quote_or_locator": "Results section, α1/α5 selectivity analysis: 'Among the newly docked C-3-aryl compounds, 1.2 (Δ = −0.7 kcal/mol), 1.4 (Δ = −0.5 kcal/mol), and 1.5 (Δ = −0.3 kcal/mol) all score more negatively at 8BHK than at 6HUP, indicating a modest preference for the α5 PAM-bound conformation'"}, {"text": "Five members of series 1 prolonged thiopental-induced sleep with the range of prolongation being 30.6 percent to 72.2 percent", "quote_or_locator": "Results section, sleep test: 'Relative to the control group, sleep duration increased by 30.6–72.2% (p ≤ 0.05 for every compound)' and 'All five test compounds prolonged thiopental-induced sleep'"}, {"text": "compounds 1.5 and 1.7 also shortened sleep-onset latency and exceeded diazepam on both parameters", "quote_or_locator": "Results section, sleep test: 'For sleep-onset latency, only compounds 1.5 and 1.7 produced a significant change, shortening the latent period by 32.4% and 31.1%, respectively (p ≤ 0.05 relative to both the control and the diazepam group)' and 'compounds 1.2, 1.5 and 1.7 also exceeded the reference drug diazepam (+33.3%)'"}, {"text": "stress reduced brain GABA 3.65-fold", "quote_or_locator": "Results section, PTSD model: 'Examination of the neurotransmitter content in the brain cytosol in PTSD showed a decrease in the concentration of the inhibitory transmitter GABA by a factor of 3.65'"}, {"text": "compound 1.5 restored this concentration to a level statistically indistinguishable from intact animals and exceeded diazepam", "quote_or_locator": "Results section, PTSD model: 'in the group treated with compound 1.5 the GABA concentration (683.6 – 21.4 pg/mL) did not differ from that of the intact animals (p = 0.60) and exceeded that of the diazepam group (p ≤ 0.05)'"}, {"text": "All compounds except 1.1 increased Slc6a4 content, an effect that diazepam did not produce", "quote_or_locator": "Results section, PTSD model: 'With the exception of compound 1.1, all test compounds significantly increased the Slc6a4 content relative to the control values (p ≤ 0.05)' and Abstract: 'All compounds except 1.1 increased Slc6a4 content, an effect that diazepam did not produce'"}, {"text": "At the α1-containing structures, all C-3 aryl compounds exceeded the predicted BZD-site affinity of the co-crystallized references diazepam, flumazenil and DMCM", "quote_or_locator": "Results section, docking overview: 'all test compounds in the 1.x series demonstrated systematically stronger affinity at the preferred BZD-site pockets compared with the corresponding co-crystallized reference ligands (diazepam, flumazenil, DMCM), across all three BZD-site-containing structures (6HUP, 6X3U, 8DD3)'"}, {"text": "Compound 1.6 achieved the highest mean affinity across the five α1 structures", "quote_or_locator": "Results section, C-3 substituent effects: 'Compound 1.6 (3,4-dimethylphenyl) achieves the highest mean affinity across the same five structures (−10.6 kcal/mol)'"}, {"text": "Compound 1.11 (11-chloro substitution) achieved −10.9 kcal/mol with Δ = −2.8 kcal/mol selectivity", "quote_or_locator": "Results section, R2 substituent effects: 'Compound 1.11 (11-Cl) yields the most negative score (−10.9 kcal/mol) and the largest BZD-site selectivity differential in the subseries (Δ = −2.8 kcal/mol)'"}, {"text": "Compound 4.5 achieved the highest BZD-site docking score in the entire dataset at −11.9 kcal/mol", "quote_or_locator": "Results section, R4 (C-6) modifications: 'The most significant finding is the docking score of 4.5 (C6-cyanomethyl) at pocket 4 (−11.9 kcal/mol), which surpasses all compounds studied to date, including the free-NH lead scaffold 1.11 (−10.9 kcal/mol) by 1.0 kcal/mol'"}], "prompt_version": "p1.0", "verdicts": [{"claim": "all C-3 aryl compounds showed modest α5 advantage irrespective of the specific aryl group", "verdict": "supported", "evidence": "Among the newly docked C-3-aryl compounds, 1.2 (Δ = −0.7 kcal/mol), 1.4 (Δ = −0.5 kcal/mol), and 1.5 (Δ = −0.3 kcal/mol) all score more negatively at 8BHK than at 6HUP, indicating a modest preference for the α5 PAM-bound conformation", "note": null}, {"claim": "Five members of series 1 prolonged thiopental-induced sleep with the range of prolongation being 30.6 percent to 72.2 percent", "verdict": "supported", "evidence": "Relative to the control group, sleep duration increased by 30.6–72.2% (p ≤ 0.05 for every compound)", "note": null}, {"claim": "compounds 1.5 and 1.7 also shortened sleep-onset latency and exceeded diazepam on both parameters", "verdict": "supported", "evidence": "For sleep-onset latency, only compounds 1.5 and 1.7 produced a significant change, shortening the latent period by 32.4% and 31.1%, respectively (p ≤ 0.05 relative to both the control and the diazepam group); compounds 1.2, 1.5 and 1.7 also exceeded the reference drug diazepam (+33.3%)", "note": null}, {"claim": "stress reduced brain GABA 3.65-fold", "verdict": "supported", "evidence": "Examination of the neurotransmitter content in the brain cytosol in PTSD showed a decrease in the concentration of the inhibitory transmitter GABA by a factor of 3.65", "note": null}, {"claim": "compound 1.5 restored this concentration to a level statistically indistinguishable from intact animals and exceeded diazepam", "verdict": "supported", "evidence": "in the group treated with compound 1.5 the GABA concentration (683.6 – 21.4 pg/mL) did not differ from that of the intact animals (p = 0.60) and exceeded that of the diazepam group (p ≤ 0.05)", "note": null}, {"claim": "All compounds except 1.1 increased Slc6a4 content, an effect that diazepam did not produce", "verdict": "supported", "evidence": "With the exception of compound 1.1, all test compounds significantly increased the Slc6a4 content relative to the control values (p ≤ 0.05)", "note": null}, {"claim": "At the α1-containing structures, all C-3 aryl compounds exceeded the predicted BZD-site affinity of the co-crystallized references diazepam, flumazenil and DMCM", "verdict": "supported", "evidence": "all test compounds in the 1.x series demonstrated systematically stronger affinity at the preferred BZD-site pockets compared with the corresponding co-crystallized reference ligands (diazepam, flumazenil, DMCM), across all three BZD-site-containing structures (6HUP, 6X3U, 8DD3)", "note": null}, {"claim": "Compound 1.6 achieved the highest mean affinity across the five α1 structures", "verdict": "supported", "evidence": "Compound 1.6 (3,4-dimethylphenyl) achieves the highest mean affinity across the same five structures (−10.6 kcal/mol)", "note": null}, {"claim": "Compound 1.11 (11-chloro substitution) achieved −10.9 kcal/mol with Δ = −2.8 kcal/mol selectivity", "verdict": "supported", "evidence": "Compound 1.11 (11-Cl) yields the most negative score (−10.9 kcal/mol) and the largest BZD-site selectivity differential in the subseries (Δ = −2.8 kcal/mol)", "note": null}, {"claim": "Compound 4.5 achieved the highest BZD-site docking score in the entire dataset at −11.9 kcal/mol", "verdict": "supported", "evidence": "The most significant finding is the docking score of 4.5 (C6-cyanomethyl) at pocket 4 (−11.9 kcal/mol), which surpasses all compounds studied to date, including the free-NH lead scaffold 1.11 (−10.9 kcal/mol) by 1.0 kcal/mol", "note": null}]}